Estrella Immunopharma, Inc. (ESLAW)
2025-06-30 | ||||
|---|---|---|---|---|
| Income taxes provision | 850 | |||
| Research and development | 4,660,301 | |||
| General and administrative | 883,727 | |||
| Total operating expenses | 5,544,028 | |||
| Loss from operations | -5,544,028 | |||
| Loss before income taxes | -5,544,028 | |||
| Net loss | -5,544,878 | |||
| Net loss applicable to common stock per share, basic (in dollars per share) | -0.15 | |||
| Net loss applicable to common stock per share, diluted (in dollars per share) | -0.15 | |||
| Weighted average common stock outstanding, basic (in shares) | 36,165,589 | |||
| Weighted average common stock outstanding, diluted (in shares) | 36,165,589 | |||